Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.32 |
| ▸ | AXL | P30530 | 2/20 | 0.32 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5579149 | 0.84 | PDPK1 (0.37) | PDPK1SMN1; SMN2PRKCIKDM4ERXFP1 | |
| SCHEMBL11315499 | 0.84 | PDPK1 (0.37) | PDPK1SMN1; SMN2PRKCIKDM4ERXFP1 | |
| SCHEMBL29999199 | 0.82 | GPR35 (0.32) | PRKCI | |
| SCHEMBL1284962 | 0.82 | GPR35 (0.32) | PRKCI | |
| SCHEMBL21880616 | 0.81 | CDK1 (0.35) | PDPK1SMN1; SMN2PRKCIKDM4ERXFP1 | |
| SCHEMBL29684826 | 0.81 | CDK1 (0.35) | PDPK1SMN1; SMN2PRKCIKDM4ERXFP1 | |
| SCHEMBL16152610 | 0.79 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL23498506 | 0.78 | PDPK1 (0.33) | PDPK1SMN1; SMN2PRKCIKDM4ERXFP1 | |
| SCHEMBL20609549 | 0.78 | PRKCI (0.34) | PDPK1SMN1; SMN2PRKCIKDM4ERXFP1 | |
| SCHEMBL10203314 | 0.78 | TNKS (0.38) | PDPK1SMN1; SMN2PRKCIKDM4ERXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-02-17 | — | — | US | disclosed |
| EP-4470609-A2 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Astrazeneca AB (SE) | 2024-12-04 | — | — | EP | disclosed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| EP-3911648-B1 | 6'-[[(1S,3S)-3-[[5-(DIFLUOROMETHOXY)-2-PYRIMIDINYL]AMINO]CYCLOPENTYL]AMINO][1(2H),3'-BIPYRIDIN]-2-ONE AS PCSK9 INHIBITOR AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-10-23 | — | — | EP | disclosed |
| CN-110913855-B | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114667282-B | Pyrimidine amide compounds and methods of treating cancer | 昊运股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240270750-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-08-15 | — | — | US | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| WO-2008083356-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008058285-A2 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008058285-A2 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-6339089-B2 | ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT | FUJIREBIO INC. (JP) | 2002-01-15 | — | — | US | disclosed |
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | FUJIREBIO INC. (FUJIREBIO KABUSHIKI KAISHA) (JP) | 2001-07-05 | — | — | US | disclosed |
| EP-0899263-A2 | Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration | Fujirebio Inc. (JP) | 1999-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006969-A1 | PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME | CYP11B2, CYP11B1, OAT | PDPK1 2693/4885SMN1; SMN2 2359/4885PRKCI 2876/4885 |
| US-20080176871-A1 | 4-CYANOPHENYLAMINO-SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INHIBITORS | CYCS, DCK, NSUN2 | PDPK1 2346/4885SMN1; SMN2 3159/4885PRKCI 2991/4885 |
| US-12552807-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, PCSK7, PCSK6 | PDPK1 2979/4885SMN1; SMN2 2006/4885PRKCI 900/4885 |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, LDLR, PCSK7 | PDPK1 2790/4885SMN1; SMN2 3043/4885PRKCI 641/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | PDPK1 338/4885SMN1; SMN2 989/4885PRKCI 98/4885 |
| US-20240270750-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | PDPK1 338/4885SMN1; SMN2 989/4885PRKCI 98/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | PDPK1 648/4885SMN1; SMN2 4804/4885PRKCI 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.